{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T17:21:22Z","timestamp":1782926482342,"version":"3.54.5"},"reference-count":62,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.vaccine.2023.01.075","type":"journal-article","created":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T01:58:30Z","timestamp":1675389510000},"page":"2439-2446","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["mRNA-based COVID-19 booster vaccination is highly effective and cost-effective in Australia"],"prefix":"10.1016","volume":"41","author":[{"given":"Rui","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher K","family":"Fairley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason J","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuming","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengyi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoru","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guihua","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingwang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.01.075_b0005","unstructured":"JHU. Coronavirus Resource Center: COVID-19 Tracking. 2022; https:\/\/coronavirus.jhu.edu. Accessed July 28, 2022."},{"issue":"2","key":"10.1016\/j.vaccine.2023.01.075_b0010","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2471\/BLT.20.267112","article-title":"Economic burden of COVID-19, China, January-March, 2020: a cost-of-illness study","volume":"99","author":"Jin","year":"2021","journal-title":"Bull World Health Organ"},{"issue":"5","key":"10.1016\/j.vaccine.2023.01.075_b0015","first-page":"218","article-title":"The Economic Implications of COVID-19 in the United States","volume":"73","author":"Ramgobin","year":"2020","journal-title":"S D Med"},{"issue":"10.1162","key":"10.1016\/j.vaccine.2023.01.075_b0020","article-title":"The economic impact of COVID-19","volume":"45","author":"McKibbin","year":"2020","journal-title":"Econ Time COVID-19"},{"key":"10.1016\/j.vaccine.2023.01.075_b0025","unstructured":"Australia. About the COVID-19 pandemic. 2021; https:\/\/www.health.gov.au\/health-alerts\/covid-19\/about. Accessed April 05, 2022."},{"key":"10.1016\/j.vaccine.2023.01.075_b0030","unstructured":"Australia. COVID-19 vaccination daily rollout update. 2022; https:\/\/www.health.gov.au\/resources\/collections\/covid-19-vaccination-daily-rollout-update. Accessed April 05, 2022."},{"issue":"2021","key":"10.1016\/j.vaccine.2023.01.075_b0035","first-page":"2015","article-title":"Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK","volume":"2021","author":"Andrews","year":"2009","journal-title":"medRxiv"},{"key":"10.1016\/j.vaccine.2023.01.075_b0040","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2114114","article-title":"Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar","author":"Chemaitelly","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.01.075_b0045","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2114228","article-title":"Waning Immunity after the BNT162b2 Vaccine in Israel","author":"Goldberg","year":"2021","journal-title":"N Engl J Med"},{"issue":"10309","key":"10.1016\/j.vaccine.2023.01.075_b0050","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(21)02183-8","article-title":"Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study","volume":"398","author":"Tartof","year":"2021","journal-title":"Lancet"},{"issue":"2021","key":"10.1016\/j.vaccine.2023.01.075_b0055","first-page":"2014","article-title":"Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern","volume":"2021","author":"Andrews","year":"2012","journal-title":"medRxiv"},{"issue":"3","key":"10.1016\/j.vaccine.2023.01.075_b0060","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.cell.2021.12.046","article-title":"SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses","volume":"185","author":"Dejnirattisai","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2023.01.075_b0065","unstructured":"Australia. ATAGI recommendations on the use of a booster dose of COVID-19 vaccine. 2022; https:\/\/www.health.gov.au\/resources\/publications\/atagi-recommendations-on-the-use-of-a-booster-dose-of-covid-19-vaccine. Accessed April 05, 2022."},{"key":"10.1016\/j.vaccine.2023.01.075_b0070","article-title":"COVID infection rates, clinical outcomes, and racial\/ethnic and gender disparities before and after Omicron emerged in the US","author":"Wang","year":"2022","journal-title":"medRxiv"},{"key":"10.1016\/j.vaccine.2023.01.075_b0075","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2119658","article-title":"Population Immunity and Covid-19 Severity with Omicron Variant in South Africa","author":"Madhi","year":"2022","journal-title":"N Engl J Med"},{"issue":"7890","key":"10.1016\/j.vaccine.2023.01.075_b0080","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/d41586-021-03794-8","article-title":"How severe are Omicron infections?","volume":"600","author":"Ledford","year":"2021","journal-title":"Nature"},{"issue":"10329","key":"10.1016\/j.vaccine.2023.01.075_b0085","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S0140-6736(22)00109-X","article-title":"Decoupling of omicron variant infections and severe COVID-19","volume":"399","author":"Madhi","year":"2022","journal-title":"Lancet"},{"issue":"7895","key":"10.1016\/j.vaccine.2023.01.075_b0090","first-page":"20","article-title":"Will Omicron end the pandemic?","volume":"602","author":"Adam","year":"2022","journal-title":"Here's what experts say Nature"},{"key":"10.1016\/j.vaccine.2023.01.075_b0095","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ijid.2022.03.008","article-title":"COVID-19 vaccination and SARS-CoV-2 Omicron (B.1.1.529) variant: a light at the end of the tunnel?","volume":"118","author":"Mattiuzzi","year":"2022","journal-title":"Int J Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2023.01.075_b0100","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.vaccine.2020.12.078","article-title":"The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness modeling to inform vaccination prioritization","volume":"39","author":"Kohli","year":"2021","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2023.01.075_b0105","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.jval.2021.09.008","article-title":"A Cost-Utility Analysis of Remote Pulse-Oximetry Monitoring of Patients With COVID-19","volume":"25","author":"Padula","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.vaccine.2023.01.075_b0110","unstructured":"Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol. 2022;7(5):396-415."},{"issue":"2","key":"10.1016\/j.vaccine.2023.01.075_b0115","doi-asserted-by":"crossref","first-page":"e278","DOI":"10.1016\/S2214-109X(21)00517-9","article-title":"Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation","volume":"10","author":"Su","year":"2022","journal-title":"Lancet Glob Health"},{"issue":"10","key":"10.1016\/j.vaccine.2023.01.075_b0120","doi-asserted-by":"crossref","first-page":"e1335","DOI":"10.1016\/S2214-109X(20)30277-1","article-title":"Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: a cost-effectiveness analysis","volume":"8","author":"Zou","year":"2020","journal-title":"Lancet Glob Health"},{"issue":"4","key":"10.1016\/j.vaccine.2023.01.075_b0125","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/ije\/dyz037","article-title":"Integrated approach for triple elimination of mother-to-child transmission of HIV, hepatitis B and syphilis is highly effective and cost-effective: an economic evaluation","volume":"48","author":"Zhang","year":"2019","journal-title":"Int J Epidemiol"},{"issue":"9","key":"10.1016\/j.vaccine.2023.01.075_b0130","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1038\/s41436-019-0457-6","article-title":"Population genomic screening of all young adults in a health-care system: a cost-effectiveness analysis","volume":"21","author":"Zhang","year":"2019","journal-title":"Genet Med"},{"key":"10.1016\/j.vaccine.2023.01.075_b0135","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ijid.2022.03.029","article-title":"Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination in the United States","volume":"119","author":"Li","year":"2022","journal-title":"Int J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2023.01.075_b0140","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jval.2021.11.1378","article-title":"The Cost-Effectiveness of Remdesivir for Hospitalized Patients With COVID-19","volume":"25","author":"Whittington","year":"2022","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.vaccine.2023.01.075_b0145","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.vaccine.2023.01.075_b0150","doi-asserted-by":"crossref","first-page":"255","DOI":"10.15585\/mmwr.mm7107e2","volume":"71","author":"Ferdinands","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2023.01.075_b0155","unstructured":"Brian J. Willett JG, Oscar A. MacLean, Craig Wilkie, Nicola Logan, Giuditta De Lorenzo, Wilhelm Furnon, Sam Scott, Maria Manali, Agnieszka Szemiel, Shirin Ashraf, Elen Vink, William T. Harvey, Chris Davis, Richard Orton,et al. The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism. 2022."},{"key":"10.1016\/j.vaccine.2023.01.075_b0160","doi-asserted-by":"crossref","unstructured":"Hiam Chemaitelly HHA, Sawsan AlMukdad, Patrick Tang, Mohammad R. Hasan, Hadi M. Yassine, Hebah A. Al Khatib, Maria K. Smatti, Peter Coyle, Zaina Al Kanaani, Einas Al Kuwari, Andrew Jeremijenko, Anvar Hassan Kaleeckal, Ali Nizar Latif, Riyazuddin Mohammad Shaik, Hanan F. Abdul Rahim, Gheyath K. Nasrallah, Mohamed Ghaith Al Kuwari, Adeel A. Butt, Hamad Eid Al Romaihi, Mohamed H. Al-Thani, Abdullatif Al Khal, Roberto Bertollini, Laith J. Abu-Raddad. Duration of protection of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 Omicron infection in Qatar. 2022.","DOI":"10.1101\/2022.02.07.22270568"},{"issue":"2","key":"10.1016\/j.vaccine.2023.01.075_b0165","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1016\/S2214-109X(20)30452-6","article-title":"Cost-effectiveness of public health strategies for COVID-19 epidemic control in South Africa: a microsimulation modelling study","volume":"9","author":"Reddy","year":"2021","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2023.01.075_b0170","unstructured":"IVAC. Results of COVID-19 Vaccine Effectiveness Studies: An Ongoing Systematic Review. 2022; https:\/\/view-hub.org\/resources. Accessed Mar 05,, 2022."},{"issue":"5","key":"10.1016\/j.vaccine.2023.01.075_b0175","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2165\/11539960-000000000-00000","article-title":"Modelling the epidemiology of infectious diseases for decision analysis: a primer","volume":"29","author":"Jit","year":"2011","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.vaccine.2023.01.075_b0180","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1177\/0272989X02239651","article-title":"Economic evaluation of vaccination programs: the impact of herd-immunity","volume":"23","author":"Brisson","year":"2003","journal-title":"Med Decis Making"},{"key":"10.1016\/j.vaccine.2023.01.075_b0185","unstructured":"OWID. COVID vaccination data. 2022; https:\/\/ourworldindata.org\/covid-vaccinations. Accessed April 05, 2022."},{"key":"10.1016\/j.vaccine.2023.01.075_b0190","unstructured":"Dean L. How much the Covid-19 vaccine will cost Australians. 2020; https:\/\/au.finance.yahoo.com\/news\/how-much-the-covid-19-vaccine-will-cost-australians-011135657.html. Accessed April 05, 2022."},{"key":"10.1016\/j.vaccine.2023.01.075_b0195","unstructured":"Rasdien P. Pharmacies and GPs are charging people for their free influenza vaccination. 2019; https:\/\/thewest.com.au\/news\/health\/pharmacies-and-gps-are-charging-people-for-their-free-influenza-vaccination-ng-b881206397z. Accessed April 05, 2022."},{"key":"10.1016\/j.vaccine.2023.01.075_b0200","unstructured":"MBS. Extension of SARS-CoV-2 (COVID-19) Laboratory Testing Items. 2022; http:\/\/www.mbsonline.gov.au\/internet\/mbsonline\/publishing.nsf\/Content\/Factsheet-Cov.LTI. Accessed Feb 27,, 2022."},{"key":"10.1016\/j.vaccine.2023.01.075_b0205","unstructured":"Test RS. Covid-19 Antigen Test - 20 PACK. 2022; https:\/\/rapidselftest.com.au\/products\/covid-19-antigen-test-20-pack. Accessed April 05, 2022."},{"key":"10.1016\/j.vaccine.2023.01.075_b0210","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1186\/s12889-016-3297-1","article-title":"Impact of quadrivalent influenza vaccine on public health and influenza-related costs in Australia","volume":"16","author":"Jamotte","year":"2016","journal-title":"BMC Public Health"},{"issue":"2","key":"10.1016\/j.vaccine.2023.01.075_b0215","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3201\/eid1602.090571","article-title":"Cost-effectiveness of pharmaceutical-based pandemic influenza mitigation strategies","volume":"16","author":"Newall","year":"2010","journal-title":"Emerg Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2023.01.075_b0220","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1177\/0310057X0503300409","article-title":"The costs of caring for patients in a tertiary referral Australian Intensive Care Unit","volume":"33","author":"Rechner","year":"2005","journal-title":"Anaesth Intensive Care"},{"key":"10.1016\/j.vaccine.2023.01.075_b0225","doi-asserted-by":"crossref","unstructured":"COVID-19 Australia: Epidemiology Report 57: Reporting period ending 16 January 2022. Commun Dis Intell (2018). 2022;46.","DOI":"10.33321\/cdi.2022.46.4"},{"key":"10.1016\/j.vaccine.2023.01.075_b0230","article-title":"Clinical Impact, Costs, and Cost-Effectiveness of Expanded SARS-CoV-2 Testing in Massachusetts","author":"Neilan","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2023.01.075_b0235","doi-asserted-by":"crossref","first-page":"e2028195","DOI":"10.1001\/jamanetworkopen.2020.28195","article-title":"Clinical Outcomes, Costs, and Cost-effectiveness of Strategies for Adults Experiencing Sheltered Homelessness During the COVID-19 Pandemic","volume":"3","author":"Baggett","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2023.01.075_b0240","unstructured":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789-1858."},{"issue":"1","key":"10.1016\/j.vaccine.2023.01.075_b0245","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12913-021-06081-4","article-title":"Cost-effectiveness of intensive care for hospitalized COVID-19 patients: experience from South Africa","volume":"21","author":"Cleary","year":"2021","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"10.1016\/j.vaccine.2023.01.075_b0250","article-title":"COVID-19 Vaccines Cost-Effectiveness Analysis: A Scenario for Iran","volume":"10","author":"Vaezi","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2023.01.075_b0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2022.03.029","article-title":"Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination in the United States","author":"Li","year":"2022","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.01.075_b0260","unstructured":"MHE. The Price Tags on the COVID-19 Vaccines. 2021; https:\/\/www.managedhealthcareexecutive.com\/view\/the-price-tags-on-the-covid-19-vaccines. Accessed April 05, 2022."},{"issue":"6569","key":"10.1016\/j.vaccine.2023.01.075_b0265","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1126\/science.acx9605","article-title":"Antiviral pills could change pandemic's course","volume":"374","author":"Couzin-Frankel","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2023.01.075_b0270","article-title":"Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness, company reports","volume":"375","author":"Mahase","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.vaccine.2023.01.075_b0275","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1080\/07853890.2022.2034936","article-title":"Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19:a meta-analysis","volume":"54","author":"Wen","year":"2022","journal-title":"Ann Med"},{"issue":"10327","key":"10.1016\/j.vaccine.2023.01.075_b0280","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0140-6736(22)00372-5","article-title":"The global COVID-19 treatment divide","volume":"399","author":"Usher","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.01.075_b0285","article-title":"African clinical trial denied access to key COVID drug Paxlovid","author":"Ledford","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2023.01.075_b0290","doi-asserted-by":"crossref","DOI":"10.1126\/science.abn4947","article-title":"Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa","author":"Pulliam","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2023.01.075_b0295","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-29579-9","article-title":"Emergence and phenotypic characterization of the global SARS-CoV-2 C.1.2 lineage","volume":"13","author":"Scheepers","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2023.01.075_b0300","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-022-04690-5","article-title":"Defining the risk of SARS-CoV-2 variants on immune protection","author":"DeGrace","year":"2022","journal-title":"Nature"},{"key":"#cr-split#-10.1016\/j.vaccine.2023.01.075_b0305.1","unstructured":"WHO. Recommendations announced for influenza vaccine composition for the 2022-2023 northern hemisphere influenza season. 2022"},{"key":"#cr-split#-10.1016\/j.vaccine.2023.01.075_b0305.2","unstructured":"https:\/\/www.who.int\/news\/item\/25-02-2022-recommendations-announced-for-influenza-vaccine-composition-for-the-2022-2023-northern-hemisphere-influenza-season, April 05, 2022."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23001263?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23001263?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:25:59Z","timestamp":1759404359000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23001263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":62,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S0264410X23001263"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.01.075","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.05.08.22274797","asserted-by":"object"}]},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"mRNA-based COVID-19 booster vaccination is highly effective and cost-effective in Australia","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.01.075","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}